The Latest Cardiac and Vascular News
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. The BIOADAPTOR RCT is a multicenter, randomized, […]
Successful DynamX Bioadaptor Live Case Presented at Singapore Live MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. The results were presented at the 30th Annual Live Interventions in Vascular Endotherapy conference […]
PARIS–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced outstanding 12-month data for the DynamX™ Coronary Bioadaptor System, the first coronary artery implant that adapts to vessel physiology. Results will be presented live tomorrow at 14:12 CEST on the Main Arena channel of the PCR e-Course as part of the Late Breaking Trials […]
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it will release at EuroPCR in Paris 9 and 12-month clinical and imaging data for the DynamX™ Novolimus-eluting Bioadaptor System, a next-generation coronary intervention system designed to treat blocked arteries via a novel “uncaging” mechanism. […]
